Hitachi High-Tech and oncology molecular diagnostics firm Gencurix have formed a strategic partnership aimed at developing cancer diagnostics and testing services.
The financial and other terms of the agreement were not disclosed.
The firms said in a statement that they will combine Hitachi High-Tech's expertise in R&D and manufacturing for IVD products and digital technology with Gencurix's technology and expertise in biomarker discovery to develop cancer diagnostic tests and testing service solutions using digital technology. Under the partnership, the companies forged an agreement to examine the feasibility of the business; they completed the agreement's checkpoints in June 2024, according to the companies.
The Tokyo-based Hitachi High-Tech and Seoul, Korea-based Gencurix said they are planning the commercialization of testing services in Japan as the next step in the collaboration.
